- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05277870
Use of Nanodropper vs. Standard Eyedropper in Patients With Glaucoma and Ocular Hypertension
3. marts 2022 opdateret af: Raghu Mudumbai, University of Washington
The purpose of this study is to evaluate the safety, efficacy, and usability of an eyedrop bottle adaptor that creates smaller eyedrops, Nanodropper, in an open-angle glaucoma/ocular hypertension patient population.
Studieoversigt
Status
Rekruttering
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This 6-month prospective, randomized, single-masked, active-controlled, crossover (AB:BA) study aims to evaluate the safety, efficacy, and usability of Nanodropper-mediated microdrops of IOP-lowering medications (experimental intervention) compared to standard eyedrops of the same medications (active comparator) in open-angle glaucoma or ocular hypertension patients at Harborview Eye Institute, for which permission has been obtained.
A pre-study visit will be held before the start of the trial in which participant clinical histories will be documented and an ocular examination will be performed.
Patients will be enrolled in the study by satisfying all the inclusion and none of the exclusion criteria.
This 6-month study will include three clinic visits: a baseline visit at t = 0, crossover visit at t = 3 months, and final visit at t = 6 months.
At the baseline visit, patients will be randomly assigned to one of two treatment groups (1:1): Group 1 will administer standard eyedrops everyday for three months before crossing over to administering Nanodropper-mediated microdrops daily for three months and Group 2 will administer Nanodropper-mediated microdrops everyday for three months before crossing over to administering standard eyedrops daily for three months.
At the visit that precedes the onset of the standard eyedrops treatment period, subjects will receive education on how to properly instill eyedrops.
At the visit that precedes the onset of the Nanodropper treatment period, patients will receive education on how to properly instill eyedrops with the Nanodropper as well as one Nanodropper per bottle of prescription eyedrops.
Patients will be instructed to use the Nanodropper with their bottle of eyedrops until the bottle is nearly depleted and they are due for a refill.
Because the Nanodropper isn't reusable, subjects will be instructed to contact the clinic for additional Nanodroppers at the time that they refill their prescriptions.
At each clinic visit, the IOP of each eye will be measured at 8 AM, 10 AM, and 12 PM using a calibrated Goldmann applanation tonometer by a masked evaluator.
Additionally, surveys designed to assess whether Nanodropper impacts the financial burden and side effect profiles associated with chronic eyedrop use, as well as the usability of Nanodropper compared to standard eyedrop bottles, will be administered.
Undersøgelsestype
Interventionel
Tilmelding (Forventet)
150
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiekontakt
- Navn: Simona Vuletic
- Telefonnummer: 206-520-9728
- E-mail: simona@uw.edu
Studiesteder
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98104
- Rekruttering
- University of Washington
-
Kontakt:
- Simona Vuletic, MD
- Telefonnummer: 206-520-9728
- E-mail: simona@uw.edu
-
Kontakt:
- Brian Gomer
- Telefonnummer: 206-520-9728
- E-mail: bgome001@uw.edu
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- ≥18 years old
- Primary open-angle glaucoma (OAG) diagnosis
- Ocular hypertension (OHT) diagnosis
- Corneal thickness <600 µm
- Use 1-2 IOP-lowering eyedrop medications that are compatible with Nanodropper
- OAG/OHT must be well-controlled (defined as ≥2 IOP measurements collected within 6 months of recruitment that are ≤21 mm Hg with variability of ±3 mm Hg)
- OAG/OHT must be progression-free (as judged by the clinician and based on ≥2 stable OCT and visual field tests collected in the 6 months prior to recruitment)
Exclusion Criteria:
- Uncontrolled glaucoma (IOP >21 mmHg)
- Use of >2 medications for treatment of OAG/OHT
- Use of eyedrop medications that are incompatible with Nanodropper
- OAG/OHT progression (as judged by the clinician within the past 6 months)
- Eye surgery including laser procedures (e.g., SLT, iridotomy) within 6 months of recruitment
- Diagnosis of acute angle-closure glaucoma and/or other retinal diseases
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Støttende pleje
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: control
Standard eyedrops of IOP-lowering medications
|
Patients will use their prescribed IOP-lowering medication using standard eyedropper on the medication bottle.
|
|
Eksperimentel: Nanodropper
Microdrops of IOP-lowering medications using Nanodropper adaptor
|
Patients will use their standard prescription for open-angle glaucoma or ocular hypertension with a Nanodropper attachment on the medication bottle.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
IOP (mm Hg)
Tidsramme: 6 months
|
Mean IOP ± SEM following three months of treatment with each modality.
The change in IOP from baseline and the percent change in IOP from baseline are supportive efficacy endpoints.
|
6 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Adverse events
Tidsramme: 6 months
|
Survey scores of treatment-related adverse events that patients experience under each treatment modality will be compared
|
6 months
|
|
Premature bottle exhaustion
Tidsramme: 6 months
|
Survey scores of how frequently patients run out of their eyedrops before insurance will cover their next refill under each treatment modality will be compared
|
6 months
|
|
Socioeconomic strain
Tidsramme: 6 months
|
Survey scores of socioeconomic strain and the financial burden associated with chronic eyedrop use under each treatment modality will be compared
|
6 months
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Efterforskere
- Ledende efterforsker: Raghu Mudumbai, University of Washington
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Hjælpsomme links
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
28. februar 2022
Primær færdiggørelse (Forventet)
30. juni 2025
Studieafslutning (Forventet)
30. juni 2025
Datoer for studieregistrering
Først indsendt
3. marts 2022
Først indsendt, der opfyldte QC-kriterier
3. marts 2022
Først opslået (Faktiske)
14. marts 2022
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
14. marts 2022
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
3. marts 2022
Sidst verificeret
1. marts 2022
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- STUDY00013248
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
INGEN
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ja
produkt fremstillet i og eksporteret fra U.S.A.
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .